Legionella Testing Market By Antibiotics 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Legionella Testing Market
Legionella Testing Market: By Antibiotics (Rifampin, Azithromycin, Ketolides, Quinolones & Macrolides), By Test Type (Sputum, Urine Antigen, Chest X-ray & Blood), By End-User (Hospitals, Commercial, Physician Offices & Labs) & By Geography-Forecast (2016-2021)
Report Code : HCR 0193
Updated Date: 23 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Legionella is a type of bacteria that can cause a serious form of pneumonia called Legionnaires disease or flu like illness. Legionella testing detects the presence of the bacteria to help diagnose the cause of a person's pneumonia. Globally, increasing incidences of legionella based diseases, and advancement in immunodiagnostic technologies and automation are the prime growth drivers of global legionella testing market. In addition, emerging economies such as China, India and others will create new opportunities for global legionella testing market. However, high cost of device and lack of awareness about legionella based diseases and outbreak are the key restraints for global legionella testing market.

This report identifies the global legionella testing market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global legionella testing market.

Legionella Testing Market

Geographically North America dominated global legionella testing market, due to growing number of patients suffering from Legionella infections and presence of large number of market players in this region. Europe is projected to have fastest growth, owing to extensive promotion and funding for healthcare facilities by the European government such as Germany and the U.K. Among all the end-users, hospital segment has the highest market share in global legionella testing market. Azithromycin drug is forecast to grow at the fastest rate throughout the forecast period. Azithromycin drug is mainly used for treating this infection in children and adults. Rapidly rising incidences of legionella based diseases in children and adults will propel the growth of Azithromycin drug.

This report segments global legionella testing market on the basis of product, technology, application, end-user, and regional market as follows:
  • Legionella Testing Market, By Antibiotics: Rifampin, Azithromycin, Ketolides, Quinolones and Macrolides
  • Legionella Testing Market, By Test Type: Sputum or Lung Tissue Test, Urine Antigen Test, Chest X-ray, and Blood Test
  • The report has focused study on legionella testing market by basis of end-user such as: Hospitals, Commercial or Private Labs, Physician Offices, and Public Health Labs
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the legionella testing market. Some of the major companies’ profiles in detail are as follows:
  • Roche Diagnostics
  • Beckman Coulter
  • Bio Rad
  • Novartis Diagnostics
  • Life Technology
1. Legionella Testing – Market Overview
2. Executive Summary
3. Legionella Testing Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Legionella Testing – Market Forces
   4.1. Drivers
      4.1.1. Increasing incidences of legionella based diseases
      4.1.2. Advancement in immunodiagnostic technologies and automation
   4.2. Restraints
      4.2.1. High cost of device
      4.2.2. Lack of awareness
   4.3. Opportunities
      4.3.1. Emerging economies
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Legionella Testing Market, By Antibiotics
   5.1. Rifampin
   5.2. Azithromycin
   5.3. Ketolides
   5.4. Quinolones
   5.5. Macrolides
6. Legionella Testing Market, By Test Type
   6.1. Sputum or Lung Tissue Test
   6.2. Urine Antigen Test
   6.3. Chest X-ray
   6.4. Blood Test
7. Legionella Testing Market, By End-User
   7.1. Hospitals
   7.2. Commercial or Private Labs
   7.3. Physician Offices
   7.4. Public Health Labs
8. Global Legionella Testing Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Legionella Testing – Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles
   10.1. Roche Diagnostics
      10.1.1. Introduction
      10.1.2. Financials
      10.1.3. Key Insights
      10.1.4. Key Strategy
      10.1.5. Product Portfolio
      10.1.6. SWOT Analysis
   10.2. Beckman Coulter
      10.2.1. Introduction
      10.2.2. Financials
      10.2.3. Key Insights
      10.2.4. Key Strategy
      10.2.5. Product Portfolio
      10.2.6. SWOT Analysis
   10.3. Bio Rad
      10.3.1. Introduction
      10.3.2. Financials
      10.3.3. Key Insights
      10.3.4. Key Strategy
      10.3.5. Product Portfolio
      10.3.6. SWOT Analysis
   10.4. Novartis Diagnostics
      10.4.1. Introduction
      10.4.2. Financials
      10.4.3. Key Insights
      10.4.4. Key Strategy
      10.4.5. Product Portfolio
      10.4.6. SWOT Analysis
   10.5. Life Technology
      10.5.1. Introduction
      10.5.2. Financials
      10.5.3. Key Insights
      10.5.4. Key Strategy
      10.5.5. Product Portfolio
      10.5.6. SWOT Analysis
   10.6. Becton Dickinson
      10.6.1. Introduction
      10.6.2. Financials
      10.6.3. Key Insights
      10.6.4. Key Strategy
      10.6.5. Product Portfolio
      10.6.6. SWOT Analysis
   10.7. Abott laboratories
      10.7.1. Introduction
      10.7.2. Financials
      10.7.3. Key Insights
      10.7.4. Key Strategy
      10.7.5. Product Portfolio
      10.7.6. SWOT Analysis
   10.8. Eiken Chemical
      10.8.1. Introduction
      10.8.2. Financials
      10.8.3. Key Insights
      10.8.4. Key Strategy
      10.8.5. Product Portfolio
      10.8.6. SWOT Analysis
   10.9. ID Biomedical
      10.9.1. Introduction
      10.9.2. Financials
      10.9.3. Key Insights
      10.9.4. Key Strategy
      10.9.5. Product Portfolio
      10.9.6. SWOT Analysis
   10.10. Thermo Fischer
      10.10.1. Introduction
      10.10.2. Financials
      10.10.3. Key Insights
      10.10.4. Key Strategy
      10.10.5. Product Portfolio
      10.10.6. SWOT Analysis
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Expert Insights
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll